In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine

Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in the broad tumor profiling panels that have struggled to gain traction but have gained momentum recently.